Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicohort study of disitamab vedotin with or without pembrolizumab in HER2-expressing advanced urothelial carcinoma
MOH_2022-08-02_011951Phase 2Recruiting
- Sponsor
- Seagen Inc.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (6 cohorts), sponsored by Seagen Inc. Primary endpoint: Primary endpoint not specified in registry. Started Jul 2022; status: recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2022-08-02_011951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-02_011951.